ECOG-ACRIN Cancer Research Group melanoma research team led by Michael Atkins, MD, receives the 2023 Paper of the Year distinction from the Journal of Clinical Oncology
A team of melanoma researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is honored with the 2023 Paper of the Year distinction by the Journal of Clinical Oncology. The recognition is for the results of the DREAMseq randomized phase 3 clinical trial. DREAMseq (EA6134) showed an optimal treatment sequence for combination therapy in patients with advanced melanoma with a BRAFV600 tumor gene mutation. The treatment sequence beginning with immunotherapy (nivolumab and ipilimumab), followed by targeted therapy (dabrafenib and trametinib) if there was disease progression, resulted ...













